Perfluorohexyloctane

Last updated

Perfluorohexyloctane
Perfluorohexyloctane.svg
Clinical data
Trade names Evotears
Miebo ( /ˈmaɪboʊ/ MY-bow)
Novatears
Other namesNOV03; 1-(perfluorohexyl)octane
AHFS/Drugs.com Monograph
MedlinePlus a623054
License data
Routes of
administration 		Eye drops
ATC code
  • None
Legal status
Legal status
Identifiers
  • 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
Formula C14H17F13
Molar mass 432.269 g·mol−1
3D model (JSmol)
  • CCCCCCCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F
  • InChI=1S/C14H17F13/c1-2-3-4-5-6-7-8-9(15,16)10(17,18)11(19,20)12(21,22)13(23,24)14(25,26)27/h2-8H2,1H3
  • Key:WRYIIOKOQSICTB-UHFFFAOYSA-N

Perfluorohexyloctane (branded as Evotears, Miebo, [a] and Novatears, among others) is a medication used for the treatment of dry eye disease. [4] It is a semifluorinated alkane. [4]

Contents

Perfluorohexyloctane has been available in multiple markets since 2015 under the brand names Evotears and Novatears, [5] and was additionally approved for medical use in the United States in May 2023 under the brand name Miebo. [4] [6] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [7]

Medical uses

Perfluorohexyloctane is indicated for the treatment of the signs and symptoms of dry eye disease. [4] [8] [9]

Availability

Perfluorohexyloctane is sold as an over-the-counter medication under the brand names Evotears and Novatears in multiple countries, [10] costing around NZ$34.00, A$30, and €30 for a one-month supply.

In the US, perfluorohexyloctane is sold under the brand name Miebo; a prescription is required. Perfluorohexyloctane (also under the brand name Miebo) was approved by Health Canada in September 2024 [11] .

Side effects

Blurred vision and conjunctival redness are among the side effects of this drug. [12]

See also

Notes and references

  1. ↑ "Notice: Multiple additions to the Prescription Drug List (PDL) [2024-10-18]". Health Canada . 18 October 2024. Retrieved 25 October 2024.
  2. ↑ "Miebo product information". Health Canada . 4 September 2024. Retrieved 27 December 2024.
  3. ↑ "Regulatory Decision Summary for Miebo". Drug and Health Products Portal. 4 September 2024. Retrieved 27 December 2024.
  4. 1 2 3 4 5 "Miebo- perfluorohexyloctane solution". DailyMed. 18 May 2023. Retrieved 8 June 2023.
  5. ↑ "URSAPHARM GmbH and Novaliq GmbH Announce European Partnership Agreement" (Press release). Retrieved 15 February 2024.
  6. ↑ "Bausch + Lomb and Novaliq Announce FDA Approval of Miebo (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease" (Press release). Bausch + Lomb Corporation. 18 May 2023. Retrieved 8 June 2023– via Business Wire.
  7. ↑ New Drug Therapy Approvals 2023. U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original (PDF) on 10 January 2024. Retrieved 9 January 2024.
  8. ↑ Ballesteros-Sánchez A, De-Hita-Cantalejo C, Sánchez-González MC, Jansone-Langine Z, de Sotomayor MA, Culig J, et al. (October 2023). "Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent". The Ocular Surface. 30: 254–262. doi:10.1016/j.jtos.2023.10.001. hdl: 11441/151762 . PMID   37813152. S2CID   263802332.
  9. ↑ Sheppard JD, Evans DG, Protzko EE (November 2023). "A review of the first anti-evaporative prescription treatment for dry eye disease: perfluorohexyloctane ophthalmic solution". The American Journal of Managed Care. 29 (14 Suppl): S251 –S259. doi: 10.37765/ajmc.2023.89464 . PMID   37930231. S2CID   265032840.
  10. ↑ "In Australia, NovaTears Eye Drops Are Available on the Pharmaceutical Benefits Scheme (PBS) from Now On" (Press release). Retrieved 15 February 2024.
  11. ↑ "Regulatory Decision Summary for Miebo". Government of Canada. 4 September 2024. Retrieved 21 July 2025.
  12. ↑ https://www.drugs.com/sfx/miebo-side-effects.html

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.